These findings suggest potential therapeutic benefits of CXCR4 antagonist therapy in reversing peripheral blood neutropenia and other pathogenic phenotypes associated with CXCR2 LOF variants in patients. The gene discussed is CXCR4; the disease is Decreased total neutrophil count.